Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Jan 03, 2018 2:46pm

183 Views

Post# 27272863

RE:RE:RE:RE:RE:Closed at 17.5 cents - smiles all around !!!

I'm optimistic this can be a 10 bagger +, That's why I'm here.
I think a good positive result in the next couple months will get us up to 90 cent range peak and settle back in the 0.50-0.70 range. I think we sit in that range for 5-7 months before the next wave up. Once we get positive results the next trial we would likely double in value taking us in the $1 - $1.40 range and sit in that till some type of partnership or big deal which I'm hoping will fetch us $2.50-$3.00, hopefully before end of year.
That's my target exit point.
Yes, this is not a comprehnsive stock analysis and has little to no backing on my numbers, just gut.
Anyone else care to speculate?

Bullboard Posts

Debt-free cannabis company set for next stage of growth